# **OSTEOPOROSIS ORDER SET**



## PATIENT WORKUP

### **BLOOD OR SERUM**

#### **Primary Workup**

- Complete Blood Count (CBC)
- Comprehensive Metabolic Panel (CMP) (includes electrolytes, renal function, calcium, liver function)
- Total Testosterone and Gonadotropin levels male patients
- Vitamin D (25[OH]D level)
- Other: \_\_\_\_\_

#### Secondary Workup

- Celiac screening
- Follicle-Stimulating Hormone (FSH) female patients
- Parathyroid hormone (PTH) level
- Phosphorus
- Serum protein electrophoresis (multiple myeloma)
   Immunofixation (usually this is done reflectively)
  - O Urine electrophoresis/immunofixation (might be required)
- Thyroid-Stimulating Hormone (TSH) level +/- free T4
- Urine \_\_\_\_\_
  - O 24-hour urinary calcium
  - O 24-hour urinary creatinine
  - Other: \_\_\_\_\_

### **SCREENING/DIAGNOSTIC TESTS**

Dual-energy X-ray Absorptiometry (DXA) with TBS, if available
O Location:
Vertebral Fracture Assessment (VFA) or X-ray*
FRAX®
Other:
o identify any new vertebral fractures that have occurred in the interval, vertebral imaging

should be repeated if there is documented height loss, new back pain, postural change, or suspicious finding on chest X-ray, following the last (or first) vertebral imaging test and in patients being considered for a temporary cessation of bisphosphonate therapy.

- **RISK FACTORS**
- Prior Fracture
  Fracture site: \_\_\_\_\_\_
  Family History of Fracture
  Smoking
  Alcohol: 3 or more units/day
  Glucocorticoids
  Other Medications
  - Anti-epileptic drugs
  - Aromatase inhibitors (Als)
  - O Loop diuretics
  - Proton pump inhibitors (PPIs)
  - O Selective serotonin reuptake inhibitor (SSRIs)
  - O Other: \_\_\_\_\_
- Secondary Osteoporosis
  - O Celiac Disease
  - O Chronic liver disease
  - O Chronic malnutrition
  - O Cystic Fibrosis (CF)
  - End-Stage Renal Disease (ESRD)
  - Gastric bypass/GI surgery
  - History of malignancy
  - O Hyperthyroidism
  - Hypogonadism
  - Inflammatory Bowel Disease (IBD)
  - O Osteogenesis Imperfecta
  - O Post organ transplant
  - Premature menopause (<45 years)
  - O Rheumatoid Arthritis
  - O Sarcoidosis/Granulomatous
  - O Steroid use
  - O Type I Diabetes
  - O Type 2 Diabetes
- Post-Menopausal: Age/Date \_\_\_\_\_

Other: \_\_\_\_\_



CDC's STEADI Algorithm for Fall Risk Screening, Assessment, and Intervention

# PATIENT EDUCATION

- Provide BHOF's patient resources & information available on the BHOF website:
  - O Falls Prevention
  - Exercise and Safe Movement
  - O Nutrition
  - O Calcium and Vitamin
  - O Medications for Prevention & Treatment
  - O Who Gets Osteoporosis?
  - Your Path to Good Bone Health<sup>™</sup> Patient Education Tool

### TREATMENT

### **CALCIUM\***

Women

Age 50 & younger Age 51 & older

1,000 mg daily 1,200 mg daily

MFN

Age 70 & younger Age 71 & older

1,000 mg daily 1,200 mg daily

\*This includes the total amount of calcium you get from food and supplements.

### **VITAMIN D\*\***

#### Women and Men

Under age 50

400-800 international units (IU) daily Age 50 & older 800-1,000 IU daily

\*\*According to the National Academy of Medicine and National Institutes of Health the safe upper limit of vitamin D is 4,000 IU per day for most adults. These recommendations are for the general healthy adult population.

### Referrals

- **Physical Therapy Referral**
- Bone Health/Endocrine/Rheumatology Referral
- Nutritionist Consult



### **OSTEOPOROSIS PHARMACOLOGIC THERAPY**

- **Bisphosphonate** 
  - O Alendronate
  - O Ibandronate
  - O Risedronate
  - O Zoledronic Acid
- RANK ligand (RANKL) inhibitor
  - O Denosumab
- Estrogen (Hormone Therapy)
  - Oral (tablet)
  - Transdermal (skin patch)
- Estrogen Agonist/Antagonist
  - O Raloxifene
  - O Tamoxifen
- Tissue Specific Estrogen Complex (TSEC)
  - O Estrogen/Bazodoxifene
- Sclerostin Inhibitor
  - O Romosozumah
- Parathyroid Hormone (PTH) Analog
  - Teriparatide
- Parathyroid Hormone-Related Protein (PTHrp) Analog O Abaloparatide
  - Infusion Center Referral

Other: \_\_\_\_\_



### **PATIENT FOLLOW-UP**

- 3 to 6 months: medication follow-up
- **1 to 2 years:** Repeat DXA, based on treatment adherence

Other:



251 18th Street S, Suite 630 • Arlington, VA 22202 1 (800) 231-4222 www.bonehealthandosteoporosis.org

BHOF Healthy Bones/Healthy Communities Program: Chicago, IL 2023 This program was made possible with support from Amgen.

© Copyright 2023 Bone Health & Osteoporosis Foundation All Rights Reserved. Developed by the Bone Health & Osteoporosis Foundation.

No part of this handout may be reproduced in any form without written permission from the Bone Health & Osteoporosis Foundation